Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer

Table 8 Relationship between progression-free survival and KRAS, BRAF, MEK, and ERK protein expression

	B	SE	Wald	df	Sig.	Exp (B)	95.0%CI of Exp (B)
							Lower limit	Upper limit
KRAS	1.200	0.506	5.623	1	0.018	3.319	1.231	8.944
MEK	-0.872	0.609	2.054	1	0.152	0.418	0.127	1.378
ERK	-0.480	0.507	0.898	1	0.343	0.619	0.229	1.670
BRAF	0.031	0.581	0.003	1	0.958	1.031	0.330	3.221
T			4.609	3	0.203
T1	1.330	1.160	1.317	1	0.251	3.783	0.390	36.714
T2	-0.780	0.858	0.827	1	0.363	0.458	0.085	2.463
T3	0.664	0.522	1.617	1	0.203	1.943	0.698	5.408
N	-0.018	0.485	0.001	1	0.970	0.982	0.380	2.541